Clementia Announces the Departure of Chief Commercial Officer
30 Novembro 2018 - 12:00PM
Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage
biopharmaceutical company innovating treatments for people with
ultra-rare bone disorders and other diseases, today announced the
departure of Eric Grinstead as the Company’s chief commercial
officer effective November 30, 2018.
“Thanks to Eric’s tenure at Clementia, we stand
today with a well-designed approach for market development and
future commercialization of palovarotene,” stated Clarissa
Desjardins, Ph.D., chief executive officer, Clementia. “As we
prepare to submit our first New Drug Application in 2019, we look
forward to further building our leadership and capabilities to
support our transformation into a fully integrated biotech
company.”
The Company has initiated a search process for a
new chief commercial officer, who is expected to have significant
product launch and market access experience. Steve Forte, chief
financial officer, will assume responsibility for the company’s
ongoing pre-commercial efforts in the interim.
About Clementia Pharmaceuticals
Inc.
Clementia is a clinical-stage company innovating
treatments for people with ultra-rare bone disorders and other
diseases with high medical need. The company is preparing for a
2019 NDA submission to the FDA to seek approval of its lead product
candidate, palovarotene, a novel RARγ agonist, for the prevention
of heterotopic ossification (HO) associated with flare up symptoms
in adults and children with fibrodysplasia ossificans progressiva
(FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional
dosing regimen of palovarotene for the treatment of FOP.
Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the
treatment of multiple osteochondromas (MO, also known as multiple
hereditary exostoses, or MHE). In addition, Clementia has commenced
a Phase 1 trial for an eye drop formulation of palovarotene for the
potential treatment of dry eye disease and is also investigating
other conditions that may benefit from RARγ therapy. For more
information, please visit www.clementiapharma.com and connect with
us on Twitter @ClementiaPharma.
Investor/Media Contact:
Joseph WalewiczClementia Pharmaceuticals Inc.+1-514-940-1080
Monique Allaire THRUST Strategic Communications
+1-617-895-9511
Clementia Pharmaceuticals Inc. (NASDAQ:CMTA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Clementia Pharmaceuticals Inc. (NASDAQ:CMTA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Clementia Pharmaceuticals Inc. da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de